PURPOSE: To explore potential indicators of the quality of end-of-life services for cancer patients that could be monitored using existing administrative data. METHODS: Quality indicators were identified and assessed by literature review for proposed indicators, focus groups with cancer patients and family members to assess candidate indicators and generate new ideas, and an expert panel ranking the meaningfulness and importance of each potential indicator using a modified Delphi approach. RESULTS: There were three major concepts of poor quality of end-of-life cancer care that could be examined using currently-available administrative data (such as Medicare claims): institution of new anticancer therapies or continuation of ongoing treatments very near death; a high number of emergency room visits, inpatient hospital admissions, or intensive care unit days near the end of life; and a high proportion of patients never enrolled in hospice, only admitted in the last few days of life, or dying in an acute-care setting. Concepts such as access to psychosocial and other multidisciplinary services and pain and symptom control are important and may eventually be feasible, but they cannot currently be applied in most data systems. Indicators based on limiting the use of treatments with low probability of benefit or indicators based on economic efficiency were not acceptable to patients, family members, or physicians. CONCLUSION: Several promising claims-based quality indicators were identified that, if found to be valid and reliable within data systems, could be useful in identifying health-care systems in need of improving end-of-life services.
PURPOSE: To explore potential indicators of the quality of end-of-life services for cancerpatients that could be monitored using existing administrative data. METHODS: Quality indicators were identified and assessed by literature review for proposed indicators, focus groups with cancerpatients and family members to assess candidate indicators and generate new ideas, and an expert panel ranking the meaningfulness and importance of each potential indicator using a modified Delphi approach. RESULTS: There were three major concepts of poor quality of end-of-life cancer care that could be examined using currently-available administrative data (such as Medicare claims): institution of new anticancer therapies or continuation of ongoing treatments very near death; a high number of emergency room visits, inpatient hospital admissions, or intensive care unit days near the end of life; and a high proportion of patients never enrolled in hospice, only admitted in the last few days of life, or dying in an acute-care setting. Concepts such as access to psychosocial and other multidisciplinary services and pain and symptom control are important and may eventually be feasible, but they cannot currently be applied in most data systems. Indicators based on limiting the use of treatments with low probability of benefit or indicators based on economic efficiency were not acceptable to patients, family members, or physicians. CONCLUSION: Several promising claims-based quality indicators were identified that, if found to be valid and reliable within data systems, could be useful in identifying health-care systems in need of improving end-of-life services.
Authors: Jimmy Yu Wai Chan; Victor Shing Howe To; Stanley Tien Sze Wong; William Ignace Wei Journal: Eur Arch Otorhinolaryngol Date: 2012-06-05 Impact factor: 2.503
Authors: Mark Corkum; Robin Urquhart; Cynthia Kendell; Fred Burge; Geoffrey Porter; Grace Johnston Journal: Cancer Causes Control Date: 2011-11-20 Impact factor: 2.506
Authors: M Frigeri; S De Dosso; O Castillo-Fernandez; K Feuerlein; H Neuenschwander; P Saletti Journal: Support Care Cancer Date: 2012-06-01 Impact factor: 3.603
Authors: L Barbera; H Seow; R Sutradhar; A Chu; F Burge; K Fassbender; K McGrail; B Lawson; Y Liu; R Pataky; A Potapov Journal: Curr Oncol Date: 2015-10 Impact factor: 3.677
Authors: Rachael L Morton; Angela C Webster; Kevin McGeechan; Kirsten Howard; Fliss E M Murtagh; Nicholas A Gray; Peter G Kerr; Michael J Germain; Paul Snelling Journal: Clin J Am Soc Nephrol Date: 2016-10-03 Impact factor: 8.237